 ROCKVILLE, Md., Oct. 6, 2021 PRNewswire -- RegeneRx Biopharmaceuticals, Inc. OTCQB: RGRX RegeneRx, a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that a new independent research paper was published identifying Thymosin Beta 4s Tβ4 potential in the diagnosis and treatment of acute kidney injury and reduction of mortality in patients with sepsis. 